
<!-- saved from url=(0064)file:///C:/Users/ygowda/Desktop/output/18646816/18646816_14.html -->
<html><head><meta http-equiv="Content-Type" content="text/html; charset=windows-1252"></head><body><table border="1">
<tbody><tr><td style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">Particulars</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">FY17</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">FY18</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">YoY Growth</span></p></td></tr>
<tr><td>
<p></p></td><td colspan="2" style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">(Rs Crs)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">{%)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">Total Revenue from Operations (Net of Excise)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">5,861</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">7,518</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">28%</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6">Pharmaceuticals</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">3,104</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">4,013</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">29%</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6">Life Science Ingredients</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">2,576</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">3,328</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">29%</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6">Drug Discovery Solutions</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">182</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">176</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">-3%</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">Total Expenditure</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">4,516</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">5,999</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">33%</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6">Other Income</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">25</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">40</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">61%</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">EBITDA from Operations</span></p></td><td>
<p></p></td><td>
<p></p></td><td>
<p></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6">Pharmaceuticals</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">975</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">1,006</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">3%</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6">Life Science Ingredients</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">434</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">632</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">46%</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6">Drug Discovery Solutions</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">26</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">19</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">-28%</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6">Corporate (Expenses)/Income</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">(65)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">(69)</span></p></td><td>
<p></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">Total</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">1,370</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">1,588</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">16%</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6">One time expenses - Acquisition related</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">0</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">(30)</span></p></td><td>
<p></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">Reported EBITDA</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">1,370</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">1,558</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">14%</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6">Depreciation and Amortization</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">291</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">415</span></p></td><td>
<p></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6">Normal</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">291</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">324</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">11%</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6">One-time</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">0</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">91</span></p></td><td>
<p></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6">Finance Cost</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">341</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">284</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">-17%</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font6" style="font-weight:bold;">Profit before Tax</span></p></td><td style="vertical-align:middle;">
<p><span class="font6" style="font-weight:bold;">738</span></p></td><td style="vertical-align:middle;">
<p><span class="font6" style="font-weight:bold;">859</span></p></td><td style="vertical-align:middle;">
<p><span class="font6" style="font-weight:bold;">16%</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6">Tax Expenses (Net)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">163</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">225</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">38%</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6">Minority Interest</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">(i)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">(8)</span></p></td><td>
<p></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">Net Profit After Tax and Minority Interest</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">576</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">643</span></p></td><td style="vertical-align:bottom;">
<p><span class="font16">12</span><span class="font6" style="font-weight:bold;">%</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">Normalised Profit after Tax</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">576</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">744</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">29%</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">Earnings Per Share - Face Value Re. 1 (Rs.)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">36.93</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">41.25</span></p></td><td>
<p></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">Normalised Earnings Per Share</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">36.93</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">47.77</span></p></td><td>
<p></p></td></tr>
<tr><td>
<p></p></td><td colspan="2" style="vertical-align:bottom;">
<p><span class="font6">(%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">(bps)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6">EBITDA Margins from Operations</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">23.4%</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">21.1%</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">(225)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6">Pharmaceuticals</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">31.4%</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">25.1%</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">(635)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6">Life Science Ingredients</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">16.8%</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">19.0%</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">215</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6">Drug Discovery Solutions</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">14.2%</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">10.5%</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">(371)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6">Net Margins</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">9.8%</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">8.6%</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">(127)</span></p></td></tr>
</tbody></table></body></html>